Tag Archives: patients with myelofibrosis

Novartis announced patients with myelofibrosis initially randomized to treatment with Jakavi® (ruxolitinib) lived longer

In two Phase III studies, Jakavi ® reduced the risk of death and maintained spleen reductions at three years compared to conventional therapy and placebo Similar survival benefit seen in patients with and without high-risk mutations Separate analysis shows Jakavi may increase … Read the full press release